Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon
The FDFA has cleared tirzepatide (Mounjaro) from Eli Lilly for the treatment of diabetes.

FDA grants fast track designation to tirzepatide, Eli Lilly’s new type 2 diabetes drug, for treating obesity

Back in May, tirzepatide was approved by the FDA for improving glycemic control among adults with type 2 diabetes.

PCI

P2Y12 inhibitor monotherapy after PCI similar to prolonged DAPT, new 3-year analysis confirms

Researchers have shared an updated analysis of the SMART-CHOICE study, focusing on major adverse cardiac and cerebrovascular events—as well as bleeding events—among PCI patients after three years. 

FDA recall. The medications involved are atenolol, which treats hypertension, and clopidogrel, which reduces the risk of an acute myocardial infarction (AMI) or stroke among patients with a history of AMI, severe chest pain or circulation problems.

FDA announces recall of 2 cardiovascular medications due to labeling mix-up

Patients face a risk of adverse events if they mistakenly take the wrong medication, according to a new warning from the FDA. 

Positive data was presented on the first-generation Symplicity (left) long-term outcomes and from the Recor ultrasound renal denervation system pivotal trial at TCT 2022. #TCT #TCT2022

Renal denervation lowered blood pressure in two late-breaking TCT trials 

Results from the Medtronic SYMPLICITY HTN-3 trial long-term results and the pivotal RADIANCE II trial for the Recor ultrasound renal denervation system lowered blood pressure effectively in drug-resistant patients.

A structural heart Presentation during the TVT 2022 conference. #TCT #TCT22 #TCT2022

TCT 2022 late-breaking clinical presentations announced

The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.

birth control the pill cardiovascular disease blood clots side effects

Blood clots much more common among obese women taking combination birth control pills

Progestin-only products may be a "safer alternative" for this patient population, according to a new analysis. 

CBD heart disease

Is CBD safe for patients with heart disease?

CBD is generally viewed as a safe, well-tolerated treatment option, but there is still limited research on how it interacts with other medications commonly prescribed by cardiologists. 

DOACs after TAVR may put some patients at risk, new meta-analysis suggests

The new study, based on data from nearly 3,000 patients, compared DOACs such as rivaroxaban, apixaban and edoxaban with single and dual antiplatelet therapy. 

Displaying 193 - 200 of 290

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup